The Scientist

» biotechnology and ecology

Most Recent

image: Biotech Buys Autoimmune Firm for $7B

Biotech Buys Autoimmune Firm for $7B

By | July 16, 2015

Celgene has purchased Receptos, developer of an experimental multiple sclerosis drug.

0 Comments

image: FDA OKs Herpes Blood Test

FDA OKs Herpes Blood Test

By | July 6, 2015

Celgene has purchased Receptos, developer of an experimental multiple sclerosis drug.

0 Comments

image: CAR-T Therapies Get $1 Billion Boost

CAR-T Therapies Get $1 Billion Boost

By | July 1, 2015

Celgene has purchased Receptos, developer of an experimental multiple sclerosis drug.

0 Comments

image: 1 + 1 = 1

1 + 1 = 1

By | July 1, 2015

Celgene has purchased Receptos, developer of an experimental multiple sclerosis drug.

0 Comments

image: Intelligence Gathering

Intelligence Gathering

By | July 1, 2015

Celgene has purchased Receptos, developer of an experimental multiple sclerosis drug.

0 Comments

image: Celladon Shutters Its R&D

Celladon Shutters Its R&D

By | June 26, 2015

Celgene has purchased Receptos, developer of an experimental multiple sclerosis drug.

0 Comments

image: Week in Review: June 22–26

Week in Review: June 22–26

By | June 26, 2015

Celgene has purchased Receptos, developer of an experimental multiple sclerosis drug.

0 Comments

image: Ravenous Invasive Worm Now in U.S.

Ravenous Invasive Worm Now in U.S.

By | June 25, 2015

Celgene has purchased Receptos, developer of an experimental multiple sclerosis drug.

0 Comments

image: Organ-on-a-Chip Gets Big Pharma Boost

Organ-on-a-Chip Gets Big Pharma Boost

By | June 18, 2015

Celgene has purchased Receptos, developer of an experimental multiple sclerosis drug.

0 Comments

image: Optogenetics Meets CRISPR

Optogenetics Meets CRISPR

By | June 15, 2015

Celgene has purchased Receptos, developer of an experimental multiple sclerosis drug.

0 Comments

Popular Now

  1. How Plants Evolved Different Ways to Make Caffeine
  2. Thomson Reuters Predicts Nobelists
    The Nutshell Thomson Reuters Predicts Nobelists

    According to citation statistics, researchers behind programmed cell death pathways and CRISPR/Cas9 are among those in line for Nobel Prizes this year.

  3. Monsanto Buys Rights to CRISPR
    The Nutshell Monsanto Buys Rights to CRISPR

    The US agribusiness secures a global, nonexclusive licensing agreement from the Broad Institute to use the gene-editing technology for agricultural applications.

  4. Reviewing Results-Free Manuscripts
    The Nutshell Reviewing Results-Free Manuscripts

    An open-access journal is trialing a peer-review process in which reviewers do not have access to the results or discussion sections of submitted papers.

RayBiotech